Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 9:2021:2261144.
doi: 10.1155/2021/2261144. eCollection 2021.

Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended

Xianglin L Du  1 , Lara M Simpson  2 , Brian C Tandy  2 , Judy Bettencourt  2 , Barry R Davis  2
Affiliations

Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended

Xianglin L Du et al. Int J Hypertens. .

Abstract

Background: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) ended in 2002, but it is important to study its long-term outcomes during the posttrial period by incorporating posttrial antihypertensive medication uses in the analysis.

Purposes: The primary aim is to explore the patterns of antihypertensive medication use during the posttrial period from Medicare Part-D data over the 11-year period from 2007 to 2017. The secondary aim is to examine the potential effects of these posttrial antihypertensive medications on the observed mortality and morbidity benefits.

Methods: This is a posttrial passive follow-up study of ALLHAT participants in 567 US centers in 1994-1998 with the last date of active in-trial follow-up on March 31, 2002, by linking with their Medicare and National Death Index data through 2017 among 8,007 subjects receiving antihypertensive drugs (3,637 for chlorthalidone, 2,189 for amlodipine, and 2,181 for lisinopril). Outcomes included posttrial antihypertensive drug use, all-cause mortality, and cardiovascular disease (CVD) mortality.

Results: Of 8007 subjects, 3,637 participants were initially randomized to diuretic (chlorthalidone). The majority (67.9%) of them still received diuretics in 2007, and 52.7%, 47.2%, and 44.0% received β-blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers (CCBs), respectively. Compared to participants who received diuretic-based antihypertensives, those who received CCB had a nonsignificantly higher risk of all-cause mortality (1.17, 0.99-1.37), whereas those who received ACE/ARB (angiotensin receptor blockers) had a significantly higher risk of all-cause mortality (1.26, 1.09-1.45). For the combined fatal or nonfatal hospitalized events, the risk of CVD was significantly higher in patients receiving CCB (1.30, 1.04-1.61) and ACE/ARB (1.49, 1.22-1.81) as compared to patients receiving diuretics.

Conclusion: After the conclusion of the ALLHAT, almost all patients switched to combination antihypertensive therapies, independently by the original drug class, and the combination therapies (mostly based on diuretics) reduced the incidence of major cardiovascular outcomes and mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study participant inclusion and exclusion and number of subjects in the final analysis.
See this image and copyright information in PMC

References

    1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Journal of the American Medical Association: The Journal of the American Medical Association . 2002;288(23):2981–2997. doi: 10.1001/jama.288.23.2981. - DOI - PubMed
    1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) Journal of the American Medical Association: The Journal of the American Medical Association . 2002;288(23):2998–3007. doi: 10.1001/jama.288.23.2998. - DOI - PubMed
    1. Piller L. B., Davis B. R., Davis B. R., et al. Validation of heart failure events in the antihypertensive and Lipid lowering treatment to prevent heart Attack trial (ALLHAT) participants assigned to doxazosin and chlorthalidone. Current Controlled Trials in Cardiovascular Medicine . 2002;3(1):p. 10. doi: 10.1186/1468-6708-3-10. - DOI - PMC - PubMed
    1. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-lowering treatment to prevent heart Attack trial (ALLHAT) Hypertension . 2003;42:239–246. - PubMed
    1. Rahman M., Brown C. D., Coresh J., Davis B. R., Eckfeldt J. H., Kopyt N. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular DiseaseA Report from the antihypertensive and lipid-lowering treatment to prevent heart Attack trial. Archives of Internal Medicine . 2004;164(9):969–976. doi: 10.1001/archinte.164.9.969. - DOI - PubMed

LinkOut - more resources